[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,221,683
  • Shares Outstanding, K 27,392
  • Annual Sales, $ 79,950 K
  • Annual Income, $ -4,600 K
  • EBIT $ 2 M
  • EBITDA $ 7 M
  • 60-Month Beta 0.86
  • Price/Sales 15.82
  • Price/Cash Flow 8,909.55
  • Price/Book 41.27

Options Overview Details

View History
  • Implied Volatility 80.99% (+1.72%)
  • Historical Volatility 60.98%
  • IV Percentile 41%
  • IV Rank 26.21%
  • IV High 188.51% on 03/05/26
  • IV Low 42.81% on 08/12/25
  • Expected Move (DTE 10) 1.87 (4.28%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 60
  • Volume Avg (30-Day) 353
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 5,773
  • Open Int (30-Day) 4,728
  • Expected Range 41.80 to 45.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.13
  • Number of Estimates 2
  • High Estimate $0.15
  • Low Estimate $0.10
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +230.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.00 +24.77%
on 07/13/26
50.18 -12.97%
on 07/29/26
+7.06 (+19.28%)
since 07/10/26
3-Month
26.66 +63.80%
on 06/03/26
50.18 -12.97%
on 07/29/26
+14.02 (+47.28%)
since 05/08/26
52-Week
14.27 +206.03%
on 02/05/26
50.18 -12.97%
on 07/29/26
+26.53 (+154.78%)
since 08/08/25

Most Recent Stories

More News
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timolol Complementary product to HEMANGEOL ® (propranolol hydrochloride)...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

FDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency market New formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE ® ...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.Chief...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals Reports Tomorrow After Missing Last Quarter's Consensus by Seven Cents

Barchart Research What to Expect from ETON Earnings ETON Generated May 13, 2026 Current Price $30.82 EPS Estimate $$0.10 Consensus Rating Strong Buy Average Move 6.46% Eton Pharmaceuticals Reports Tomorrow...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 43.67 (-2.09%)
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation Eton has integrated full Eton Cares patient support, including $0 co-pay for eligible...

ETON : 43.67 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

3rd Resistance Point 47.20
2nd Resistance Point 46.28
1st Resistance Point 44.97
Last Price 43.67
1st Support Level 42.74
2nd Support Level 41.82
3rd Support Level 40.51

See More

52-Week High 50.18
Last Price 43.67
Fibonacci 61.8% 36.46
Fibonacci 50% 32.22
Fibonacci 38.2% 27.99
52-Week Low 14.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.